Search

Displaying results 281 - 290 of 10000 in total
  1. Drug

    Irinotecan

    go.drugbank.com/drugs/DB00762
    ApprovedInvestigational

    [A263381] As an anticancer drug, irinotecan was first commercially available in Japan in 1994 to treat various cancers such as lung, cervical and ovarian cancer. … [A263376] The bis-piperidine side chain in the structure of irinotecan bestows enhanced water solubility.

    Synonyms: (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-1H-indol-1-ylCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  2. Drug

    Calcipotriol

    go.drugbank.com/drugs/DB02300
    ApprovedInvestigational

    Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

    Mixtures: PSORCUTAN BETA 50 MCG/G + 500 MCG/G MERHEM , 30 GR, DAIVOBET GEL 50 MCG + 0.5 MG/ GProducts: PSORCUTAN % 0.005 MERHEM, 100 G, DAIVONEX OINTMENT 50 mcg/g
  3. Drug

    Promethazine

    go.drugbank.com/drugs/DB01069
    ApprovedInvestigational

    Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. … [A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]

    Mixtures: ARTU 100 ML SURUPCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  4. Drug

    Hydroxyprogesterone caproate

    go.drugbank.com/drugs/DB06789
    Approved

    Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. … FDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy

    Mixtures: GRAVIDINONA 2 MLCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Inducers
  5. Drug

    Pinaverium

    go.drugbank.com/drugs/DB09090
    ApprovedInvestigational

    Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada. … Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets.

    Mixtures: BROMUX D® 100/300 MG CÁPSULA.Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Xylometazoline

    go.drugbank.com/drugs/DB06694
    Approved

    In some countries, it is available as combination products with [ipratropium], [domiphen], or [dexpanthenol].

    Mixtures: XYLAZOL PEDİYATRİK 0,5 MG/ML + 50 MG/ML BURUN SPREYİ, ÇÖZELTİ, 10 ML, nasic - Nasenspray 10 mg/500 mgCategories: Sympathomimetics Used as Decongestants
  7. Drug

    Protamine sulfate

    go.drugbank.com/drugs/DB09141
    ApprovedInvestigational

    Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps … As a consequence, whenever protamine sulfate use is clinically considered, careful consideration must be given as to whether the use of the agent could decrease the safety of the procedure or worsen the

    Products: PAMINTU 10 MG/ML ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON 5 ML, 10 ADET, PROTAMINE SULPHATE INJECTION BP 50 mg/5 ml
  8. Drug

    Ginkgo biloba

    go.drugbank.com/drugs/DB01381
    ApprovedInvestigationalNutraceutical

    diseases, such as dementia. … [A232384] _Ginkgo biloba_ was investigated in preliminary studies for a variety of therapeutic purposes such as improving cardiovascular health, sexual dysfunction, psychiatric disorders, skin disorders

    Mixtures: MEGINGO 10/50 MG EFERVESAN TABLET, 100 ADET, MEGINGO 20/50 MG EFERVESAN TABLET, 100 ADETCategories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP1A2 Inhibitors
  9. Drug

    Doxorubicin

    go.drugbank.com/drugs/DB00997
    ApprovedInvestigational

    [A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsSynonyms: (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside, (8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
  10. Drug

    Ferric carboxymaltose

    go.drugbank.com/drugs/DB08917
    ApprovedInvestigational

    It was FDA approved on July 25, 2013.

    Products: Ferapplic 500 mg/10 ml Enjeksiyonluk/İnfüzyonluk Çözelti, 5 flakon, Ferapplic 500 mg/10 ml Enjeksiyonluk/İnfüzyonluk Çözelti, 1 flakon